WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs.

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody. Lilly tried to influence the panel by announcing it would offer the drug at a wholesale price 40% lower than the competition.

BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.

LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong Kong.

Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China rights to three other siRNA molecules.